Varian, a Siemens Healthineers company, announced that the first participant has been treated in the RADIATE-VT clinical trial (NCT 05765175) at Washington University School of Medicine in St. Louis, Missouri. RADIATE-VT is the first international, multi-centre, randomized controlled trial to evaluate the safety and efficacy of cardiac radioablation (CRA) compared to catheter ablation for patients with high-risk, refractory ventricular tachycardia (VT). The cardiac radioablation treatments will be planned and delivered with Varian's CRA system.
Siemens Healthineers is predicting that its $16.4 billion takeover of Varian will drive revenues in the coming years, tipping the acquired unit to post double-digit annual sales growth from 2023 to 2025.
Outside of pandemic-related diagnostic sales, Siemens posted growth of 11.8% compared to the year before, driven by expansions in its core businesses.
FDA granted breakthrough device status to Varian's Embozene microspheres in the treatment of symptomatic knee osteoarthritis. The microspheres, which are already used to treat some cancers and other diseases, are injected into the artery in the knee to drive embolization. By blocking up the vessel, the microspheres are designed to reduce blood flow to the affected region and thereby limit the inflammatory process and pain.
PALO ALTO, Calif., Oct. 13, 2021 /PRNewswire/ -- Varian, Inc., a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its Embozene® microspheres for genicular artery embolization (GAE) for symptomatic knee osteoarthritis. Embozene is a medical device that is FDA cleared for the embolization of hypervascular tumors, arteriovenous malformations, uterine fibroids and benign prostatic hyperplasia.
Varian, a Siemens Healthineers company, has announced that China Medical University Hospital in Central Taiwan treated its first patient with Ethos™ therapy, making it the first hospital in Taiwan and within the Greater China region to use Ethos therapy for advanced cancer treatment.
Varian, a Siemens Healthineers company, announced today that China Medical University Hospital in Central Taiwan treated its first patient with Ethos™ therapy, making it the first hospital in Taiwan and within the Greater China region to use Ethos therapy for advanced cancer treatment.
Taking an important step to accelerate innovation of new multidisciplinary solutions to address the growing global cancer burden, Varian Medical Systems has announced that it has entered into a definitive agreement to acquire Cancer Treatment Services International (CTSI) for $283 million. Privately held, CTSI operates the American Oncology Institute in Hyderabad, India and 10 multidisciplinary—radiation, medical and surgical oncology— cancer centers across the Indian subcontinent as well as a U.S.-based Oncology Solutions division that provides cancer care professional services to healthcare providers worldwide.
Varian to acquire Cancer Treatment Services International for $283M